Isofol Medical CFO and Deputy CEO Gustaf Albèrt to step down during 2023
GOTHENBURG, Sweden, December 21, 2022 – Isofol Medical AB (publ) announced today that Chief Financial Officer (CFO) Gustaf Albèrt, who […]
Corporate Information
CEO Ulf Jungnelius to leave Isofol Medical on June 1, 2023
GOTHENBURG, Sweden, November 28, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that Chief Executive Officer Dr.
Final data from the AGENT study confirms topline results
GOTHENBURG, Sweden, November 25, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that analysis of the AGENT
Isofol appoints nomination committee ahead of the Annual General Meeting 2023
GOTHENBURG, Sweden, November 3, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
Invitation to presentation of Isofol’s report for the third quarter of 2022
GOTHENBURG, Sweden, October 27, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for
Isofol reports data from the AGENT study
GOTHENBURG, Sweden, 7 september 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) today reported data from the AGENT study
Isofol provides update on the AGENT study
GOTHENBURG, Sweden, August 31, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announced that, having received access to
Invitation to presentation of Isofol´s report for the second quarter of 2022
GOTHENBURG, Sweden, August 15, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for
Isofol Announces Topline Results of Phase III AGENT Study – Did Not Meet Primary or Key Secondary Endpoints
GOTHENBURG, Sweden, August 3, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced topline results that neither the
Isofol receives approval of biomarker analysis patent and intention-to-grant patent application for study dose regimen in Europe
GOTHENBURG, Sweden, July 26, 2022 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq Stockholm: ISOFOL), today announced the European approval for a